Thus, AIM2 in NSCLC exerts tumor‐promoting effects in an inflammasome‐dependent manner and regulation of mitochondrial dynamics, presumably triggering an IL‐1β/STAT3 response by the nuclear factor‐κB (NF‐κB)/COX‐2/HIF‐1α pathway and contributing to the MAPK/ERK pathway activation. The gene discussed is AIM2; the disease is non-small cell lung carcinoma.